Physician profile
Adolfo R Suarez
NPI 1104910157
$7,572.49
in general payments reported to CMS, 2019-2025
35 companies · $1,332 in 2025
The $1,332 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $2,019 · 2021: $918 · 2022: $552 · 2023: $1,050 · 2024: $1,175 · 2025: $1,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,556.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $1,211.85 | 2020-2023 | Nuzyra |
| Novo Nordisk INC | $1,084.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $754.16 | 2019-2025 | Airsupra, Farxiga |
| Supernus Pharmaceuticals, INC. | $725.32 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $432.33 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $367.80 | 2019-2025 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $340.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.78 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $215.41 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $214.25 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $195.03 | 2024-2025 | Caplyta |
| Pfizer INC. | $194.78 | 2019-2025 | |
| Amgen INC. | $182.66 | 2019-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $180.72 | 2019-2021 | |
| Glaxosmithkline, LLC. | $175.69 | 2019-2025 | Trelegy Ellipta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $167.71 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $144.70 | 2019-2022 | |
| Abbvie INC. | $108.71 | 2021-2025 | |
| Amarin Pharma, INC. | $94.64 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $65.40 | 2020-2023 | Seglentis, Livalo |
| Takeda Pharmaceuticals U.S.A., INC. | $57.06 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $52.86 | 2019-2023 | Jornay Pm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.02 | 2020-2023 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $41.89 | 2023 | Quviviq |
| Exact Sciences Corporation | $41.36 | 2024-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $39.64 | 2020 | |
| Mylan Specialty L.P. | $27.17 | 2020 | |
| Dexcom, INC. | $23.86 | 2024 | Dexcom G6 Transmitter |
| Lucid Diagnostics INC. | $21.37 | 2024 | |
| Genentech USA, INC. | $20.64 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $20.24 | 2020 | |
| Eisai INC. | $19.52 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $19.08 | 2021 | |
| Currax Pharmaceuticals LLC | $14.01 | 2023 | Contrave, Onzetra Xsail |
| Allergan, INC. | $11.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adolfo Suarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.